Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (357)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03047603 | Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC | completed | — | 4,005 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06265883 | Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT | completed | — | 205 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Feb 20, 2024 |
| clinicaltrials |
| NCT06261138 | Survival Analysis: TACE vs. Combination Therapy in HCC | completed | — | 279 | Zhejiang UniversityOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT03893695 | Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) | completed | Phase 1 / Phase 2 | 20 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06245798 | Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension | completed | — | 3,000 | Tang-Du HospitalOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06233708 | Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant | completed | — | 2,092 | Asan Medical CenterOTHER | 0 | Jan 31, 2024 | clinicaltrials |
| NCT06199297 | Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma | completed | — | 188 | Sun Yat-sen UniversityOTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT02650271 | Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC | completed | Phase 3 | 240 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT02329860 | Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP) | completed | Phase 3 | 400 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 22, 2024 | clinicaltrials |
| NCT03535259 | Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma(SIRAHCC) | completed | Phase 2 | 86 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT01004978 | Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | completed | Phase 3 | 235 | National Cancer Institute (NCI)NIH | 1 | Jan 3, 2024 | clinicaltrials |
| NCT00683631 | TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)(TheraSphere) | completed | — | 183 | University of LouisvilleOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT01624285 | Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer | completed | Phase 2 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT03006926 | A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma | completed | Phase 1 | 104 | Eisai Co., Ltd.INDUSTRY | 7 | Dec 13, 2023 | clinicaltrials |
| NCT05007548 | to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve | completed | Phase 2 | 30 | National Atomic Research Institute, TaiwanOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT00355238 | A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer | completed | Phase 2 | 137 | Bristol-Myers SquibbINDUSTRY | 8 | Dec 1, 2023 | clinicaltrials |
| NCT05498779 | Ablation of Hepatocellular Carcinoma: a Nationwide Study | completed | — | 490 | Rigshospitalet, DenmarkOTHER | 1 | Nov 28, 2023 | clinicaltrials |
| NCT01447667 | Magnetic Resonance Elastography (MRE) as a Predictor of HCC Recurrence After Radiofrequency Ablation (RFA)(MRE) | completed | N/A | 72 | Seoul National University HospitalOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT01910909 | Stereotactic Body Radiotherapy for Unresectable Hepatocellular Carcinoma(SBRT for HCC) | completed | N/A | 56 | Samsung Medical CenterOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04391348 | Combination PET With 18F-fluorodeoxyglucose (18F-FDG) and 18 F-choline in Patient With HCC(PET-HCC01) | completed | N/A | 230 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02279719 | A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 97 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT02460835 | A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma | completed | N/A | 77 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT04297254 | A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC | completed | Phase 4 | 50 | Eisai Pharmaceuticals India Pvt. LtdINDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT02232633 | A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer | completed | Phase 2 | 45 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT02834780 | Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma | completed | Phase 1 | 128 | H3 Biomedicine Inc.INDUSTRY | 11 | Nov 13, 2023 | clinicaltrials |
| NCT01556490 | Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer(STOP-HCC) | completed | N/A | 526 | Boston Scientific CorporationINDUSTRY | 11 | Nov 8, 2023 | clinicaltrials |
| NCT04569799 | Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE(TACE) | completed | Phase 4 | 26 | Milton S. Hershey Medical CenterOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT03434379 | A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma(IMbrave150) | completed | Phase 3 | 558 | Hoffmann-La RocheINDUSTRY | 17 | Oct 23, 2023 | clinicaltrials |
| NCT03735628 | An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 16 | BayerINDUSTRY | 2 | Oct 6, 2023 | clinicaltrials |
| NCT04555265 | Cytokine Change in Hepatocellular Carcinoma Treated by Thermal Ablation | completed | N/A | 60 | Chinese University of Hong KongOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT03702998 | Hepatocellular Carcinoma in HIV-infected Individuals in Asian Population | completed | — | 3,900 | Chinese University of Hong KongOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT04942665 | Low Dose ICG for Biliary Tract and Tumor Imaging(ICG) | completed | Phase 2 | 60 | University of FloridaOTHER | 1 | Aug 30, 2023 | clinicaltrials |
| NCT06013657 | Surgical Resection for Hepatocellular Carcinoma | completed | — | 91 | Dr Cipto Mangunkusumo General HospitalOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT04920019 | Opioid Sparing Effect of Thoracic Epidural Analgesia for Open Upper Abdominal Surgery | completed | N/A | 140 | Mahidol UniversityOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT06005883 | Surgical Outcome of HCC With Portal Vein Tumor Thrombosis on the Basis of Risk Scoring | completed | — | 332 | Keimyung University Dongsan Medical CenterOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT00539643 | Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma | completed | Phase 2 | 101 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05643391 | Safety and Feasibility of Radioembolization Using Ho-166 in Patients With Unresectable Hepatocellular Carcinoma(RETOUCH) | completed | N/A | 20 | Erasme University HospitalOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT04642547 | Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma | completed | N/A | 30 | RenJi HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05291338 | Pharmacogenetic Study in Hepatocellular Carcinoma Patients. | completed | — | 107 | Rehab WeridaOTHER | 1 | Jul 28, 2023 | clinicaltrials |
| NCT03347292 | Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC | completed | Phase 1 | 58 | BayerINDUSTRY | 2 | Jul 25, 2023 | clinicaltrials |
| NCT03572582 | Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma(IMMUTACE) | completed | Phase 2 | 49 | AIO-Studien-gGmbHOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT04975932 | Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study(CHANCE001) | completed | — | 826 | Zhongda HospitalOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT00699816 | Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients | completed | Phase 3 | 230 | GC Cell CorporationINDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT02424955 | Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation | completed | N/A | 11 | Stanford UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT04823754 | Perception of the Doctor/Patient Relationship, Disease and Treatment Among Physicians and Their Patients Treated With Systemic Therapy for Hepatocellular Carcinoma "PERCEPTION1"(PERCEPTION1) | completed | — | 150 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT03222076 | Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer | completed | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT02795429 | Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC | completed | Phase 1 / Phase 2 | 89 | Novartis PharmaceuticalsINDUSTRY | 8 | Jul 3, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT01890291 | Long Term Follow-Up Study of Immuncell-LC Group and Non-Treatment Group in Hepatocellular Carcinoma Patients.(Immuncell-LC) | completed | — | 162 | GC Cell CorporationINDUSTRY | 1 | Jun 26, 2023 | clinicaltrials |
| NCT01897610 | Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC | completed | Phase 2 | 40 | GC Cell CorporationINDUSTRY | 1 | Jun 26, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 20, 2024source: clinicaltrials